Suppression of seasonal increase in serum interleukin-5 is linked to the clinical efficacy of immunotherapy for seasonal allergic rhinitis

Acta Oto-Laryngologica, Supplement

Volumn , Issue 538, 1998, Pages 133-142

  Hayashi, Motoyo ^a   Ohashi, Yoshihiro ^a   Tanaka, Ayaki ^a   Kakinoki, Yasushi ^a   Nakai, Yoshiaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cryptomeria japonica; Japanese cedar pollen; Pollen allergy

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; POLLEN EXTRACT; ALLERGEN; HISTAMINE H1 RECEPTOR ANTAGONIST; INTERLEUKIN 2 RECEPTOR;

ADULT; ALLERGENICITY; ALLERGIC RHINITIS; ANTIGEN SPECIFICITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEASONAL VARIATION; STATISTICAL ANALYSIS; TREATMENT PLANNING; BLOOD; DESENSITIZATION; HAY FEVER; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POLLEN; SEASON;

ADULT; ALLERGENS; COMBINED MODALITY THERAPY; DESENSITIZATION, IMMUNOLOGIC; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INTERLEUKIN-5; MIDDLE AGED; POLLEN; RECEPTORS, INTERLEUKIN-2; RHINITIS, ALLERGIC, SEASONAL; SEASONS;

EID: 0031593518     PISSN: 03655237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ricci M, Rossi O, Bertoni M, Matucci A. The importance of TH2-like cells in the pathogenesis of airway allergic inflammation. Clin Exp Allergy 1993; 23: 360-9.
2. Mosmann TR, Coffman RL. Two types of mouse helper T-cell clone; implication for immune regulation. Immunol Today 1987; 8: 223-7.
3. Spiegelberg HL, Beck L, Stevenson DD, Ishioka GY. Recognition of T-cell epitopes and lymphokine secretion by rye grass allergen Lolium perenne I-specific human T-cell clones. J Immunol 1994; 152: 4706-11.
4. Kay AB, Ying S, Varney VA. Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991; 173: 775-8.
5. Robinson DS, Hamid Q, Ying S, et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Eng J Med 1992; 326: 298-304.
6. Tanaka A, Ohashi Y, Kakinoki Y, Nakai Y. Immunotherapy suppresses both Th1 and Th2 responses by allergen stimulation, but suppression of Th2 response is a more important mechanism related to the clinical efficacy of immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998; 48: 201-11.
7. Rothemberg ME, Peterson J, Stevens RL, et al. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced variability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143: 2311-6.
8. Kay AB. T lymphocytes and their products in atopic allergy and asthma. Int Arch Allergy Appl Immunol 1991; 94: 189-93.
9. Leung DYM, Geha RS. Regulation of the human IgE antibody response. Int Rev Immunol 1987; 2: 75-91.
10. Schleimer RP, Sterbinsky SA, Kaiser J, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992; 148: 1086-92.
11. Ohashi Y, Nakai Y, Tanaka A, et al. Allergen-induced synthesis of interleukin-5, but not of IgE, is a key mechanism linked to symptomatic episodes of seasonal allergic rhinitis in sensitized individuals. Scand J Immunol 1998; 47: 596-602.
12. Brunet C, Bedard PM, Lavoie A, et al. Allergic rhinitis to ragweed pollen. 1. Reassessment of the effects of immunotherapy on cellular and humoral responses. J Allergy Clin Immunol 1992; 89: 76-86.
13. Pence HL, Mitchell DQ, Greely RL. Immunotherapy for mountain cedar pollinosis: a double-blind controlled study. J Allergy Clin Immunol 1976; 58: 39-49.
14. Ohashi Y, Tanaka A, Kakinoki Y, et al. Effect of immunotherapy on seasonal changes in serum-specific IgE and IgG4 in patients with pollen allergic rhinitis. Laryngoscope 1997; 107: 1270-5.
15. Ohashi Y, Nakai Y, Kakinoki Y, et al. Immunotherapy affects the seasonal increase in specific IgE and interleukin-4 in the serum of patients with seasonal allergic rhinitis. Scand J Immunol 1997; 46: 67-77.
16. Ohashi Y, Nakai Y, Tanaka A, et al. Immunotherapy decreases seasonal rise in soluble CD23 in seasonal allergic rhinitis. Laryngoscope 1998; 108: 706-11.
17. 41st World Medical Assembly. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ 1990; 24: 606-9.
18. Ohashi Y, Ohno Y, Okamoto H, et al. Clinical evaluation of lumiward immunoassay system for measurement of Japanese cedar pollen-specific IgE antibodies. Pract Otol 1996; 89: 575-81.
19. Chilosi M, Semenzato G, Cetto G, et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant γ-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530-5.
20. Ohashi Y, Nakai Y, Sakamoto H, et al. Serum levels of soluble interleukin- 2 receptor in patients with perennial allergic rhinitis before and after immunotherapy. Ann Allergy Asthma Immunol 1996; 77: 203-8.
21. Ohashi Y, Nakai Y, Okamoto H, et al. Significant correlation between symptom score and IgG4 antibody titer following long-term immunotherapy for perennial allergic rhinitis. Ann Otol Rhinol Laryngol 1997; 106: 483-9.
22. Ohashi Y, Nakai Y, Tanaka A, et al. Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. Ann Asthma Allergy Immunol 1997; 79: 213-20.
23. Ohashi Y, Nakai Y, Tanaka A, et al. Seasonal rise in interleukin-4 during pollen season is related to seasonal rise in specific IgE for pollens but not for mites. Acta Otolaryngol (Stockh) 1998; 118: 243-7.
24. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007-8.
25. + T lymphocytes. J Immunol 1982; 129: 1076-9.
26. Farrar JJ, Benjamin WR, Hilfker ML, et al. The biochemistry, biology and role of interleukin-2 in the induction of cytotoxic T-cell antibody-forming B cell responses. Immunol Rev 1982; 63: 129-66.
27. Wladmann TA. The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation. Environ Health Perspect 1987; 75: 11-5.
28. Robb RJ, Munck A, Smith KA. T-cell growth factor receptors. Quantitation, specificity and biological relevance. J Exp Med 1981; 154: 1455-74.
29. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-7.
30. Pui CH. Serum interleukin-2 receptor: clinical and biological implications. Leukemia 1989; 3: 323-4.
31. Kahaleh MB, Le Roy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Inter Med 1989; 110: 446-50.
32. Balderas RS. Elevated titers of cell-free interleukin 2 receptor in serum of lupus mice. J Immunol 1987; 139: 1496-550.
33. Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988; i: 1129-1132.
34. Ohashi Y, Nakai Y, Okamoto H, et al. Serum level of interleukin-4 in patients with perennial allergic rhinitis during allergen-specific immunotherapy. Scand J Immunol 1996; 43: 680-6.
35. Ohashi Y, Nakai Y, Tanaka A, et al. Ten-year follow-up study of allergen-specific IgE and IgG4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients treated with immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998; 47: 167-78.